BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 12039923)

  • 1. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
    Disis ML; Gooley TA; Rinn K; Davis D; Piepkorn M; Cheever MA; Knutson KL; Schiffman K
    J Clin Oncol; 2002 Jun; 20(11):2624-32. PubMed ID: 12039923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
    Disis ML; Grabstein KH; Sleath PR; Cheever MA
    Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
    Disis ML; Schiffman K; Guthrie K; Salazar LG; Knutson KL; Goodell V; dela Rosa C; Cheever MA
    J Clin Oncol; 2004 May; 22(10):1916-25. PubMed ID: 15143085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
    Knutson KL; Schiffman K; Cheever MA; Disis ML
    Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.
    Disis ML; Schiffman K; Gooley TA; McNeel DG; Rinn K; Knutson KL
    Clin Cancer Res; 2000 Apr; 6(4):1347-50. PubMed ID: 10778962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles.
    Salazar LG; Fikes J; Southwood S; Ishioka G; Knutson KL; Gooley TA; Schiffman K; Disis ML
    Clin Cancer Res; 2003 Nov; 9(15):5559-65. PubMed ID: 14654536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
    Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
    Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
    Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.
    Knutson KL; Schiffman K; Disis ML
    J Clin Invest; 2001 Feb; 107(4):477-84. PubMed ID: 11181647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
    J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
    Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.
    Disis ML; Rinn K; Knutson KL; Davis D; Caron D; dela Rosa C; Schiffman K
    Blood; 2002 Apr; 99(8):2845-50. PubMed ID: 11929774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
    Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
    Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.
    Disis ML; Gralow JR; Bernhard H; Hand SL; Rubin WD; Cheever MA
    J Immunol; 1996 May; 156(9):3151-8. PubMed ID: 8617935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients.
    Disis ML; Goodell V; Schiffman K; Knutson KL
    J Clin Immunol; 2004 Sep; 24(5):571-8. PubMed ID: 15359116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
    Park JW; Melisko ME; Esserman LJ; Jones LA; Wollan JB; Sims R
    J Clin Oncol; 2007 Aug; 25(24):3680-7. PubMed ID: 17704416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
    Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer.
    Disis ML; Knutson KL; Schiffman K; Rinn K; McNeel DG
    Breast Cancer Res Treat; 2000 Aug; 62(3):245-52. PubMed ID: 11072789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer vaccines targeting the HER2/neu oncogenic protein.
    Disis ML; Schiffman K
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):12-20. PubMed ID: 11774201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.